Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587144 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01587144 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT01587144, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effectiveness of an investigational drug called lucanthone, when combined with temozolomide (TMZ) and radiation in the treatment of Glioblastoma Multiforme (GBM).
Interventions
- DRUG Placebo
- RADIATION Radiation
- DRUG Temozolomide (TMZ)
- DRUG Lucanthone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-06-19 |
| Est. Completion | 2013-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587144
The ClinicalTrials.gov registry entry for NCT01587144 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01587144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01587144 about?
NCT01587144 is a clinical study titled "Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)". The purpose of the study is to determine the effectiveness of an investigational drug called lucanthone, when combined with temozolomide (TMZ) and radiation in the treatment of Glioblastoma Multiforme (GBM).
What is the current status of trial NCT01587144?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-06-19. Estimated completion is 2013-04-15.
What interventions are being tested in trial NCT01587144?
The interventions under investigation include: Placebo (DRUG), Radiation (RADIATION), Temozolomide (TMZ) (DRUG), Lucanthone (DRUG).
Who is sponsoring clinical trial NCT01587144?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.